TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33763756
Drug: Emerging therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerging therapies including post-neoadjuvant chemotherapy strategies, PARP inhibitors, immune checkpoint inhibitors, antibody-drug conjugates, and combination therapies (AKT/PI3K/mTOR-inhibitors, immunotherapeutic agents, CDK-inhibitors, antiandrogens, antiangiogenics, histone deacetylase inhibitors)
Study: 33764309
Drug: Essential Coaching
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential Coaching for Every Mother program (text message program with 53 messages sent twice a day for the first 2 weeks and daily for weeks 3 through 6)
Study: 33764552
Drug: Microneedle fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedle fractional radiofrequency treatment
Study: 33764600
Drug: Sodium levofolinate
Normalized name: sodium levofolinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium levofolinate (Na-Lev) in combination with 5-fluorouracil (5-FU) administered in a single 48-hour pump
Study: 33764600
Drug: Calcium levofolinate
Normalized name: calcium levofolinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium levofolinate (Ca-Lev) in combination with 5-fluorouracil (5-FU) with a 2-hour infusion
Study: 33764809
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with CD19.28ζ-CAR T cells followed by alloHSCT
Study: 33764812
Drug: Reasons for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reasons for missing medications
Study: 33764991
Drug: Conventional obesity
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional obesity treatment (control group)
Study: 33765041
Drug: GlycA (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: GlycA (mean plasma level 381 μmol/L)
Study: 33765164
Drug: Adjuvant therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapies (tyrosine kinase inhibitors or mTOR inhibitor)
Study: 33765419
Drug: Iptacopan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iptacopan (200 mg twice daily)
Study: 33765926
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NGS panel with AFP (20 ng/mL)
Study: 33766502
Drug: Dose-escalated tumour
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated tumour boost radiotherapy
Study: 33766844
Drug: Community delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community delivery of intermittent preventive treatment (C-IPTp) with sulfadoxine-pyrimethamine at each scheduled antenatal care (ANC) visit.
Study: 33767061
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of kidney replacement therapy (KRT)
Study: 33767061
Drug: Delayed initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Delayed initiation of kidney replacement therapy (KRT)
Study: 33767093
Drug: C5 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C5 inhibitors and daptomycin
Study: 33767093
Drug: Early antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early antibiotics
Study: 33767648
Drug: iACTwithPain intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iACTwithPain intervention (eight weekly self-management sessions)
Study: 33768419
Drug: Cemiplimab 350
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 350 mg Q3W
Study: 33768419
Drug: Cemiplimab 3
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 3 mg/kg Q2W
Study: 33769355
Drug: Saroglitazar 4
Normalized name: Saroglitazar 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saroglitazar 4 mg daily for 16 weeks
Study: 33769497
Drug: Apatinib, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib, an anti-angiogenic tyrosine kinase inhibitor, administered once daily until disease progression, unmanageable toxicity, withdrawal, or death.
Study: 33770527
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of Daily Living (ADL)
Study: 33770575
Drug: Palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125 mg orally on days 1-21 of a 28-day cycle)
Study: 33771853
Drug: Evofosfamide (400-640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evofosfamide (400-640 mg/m2) in combination with Ipilimumab
Study: 33772397
Drug: Intraoral neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoral neuromuscular stimulation device (NMES), used for 20 min once daily for a 6-week period.
Study: 33772428
Drug: Antithrombotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic treatment (including Factor Xa inhibitors/direct thrombin inhibitors and antiplatelet therapy)
Study: 33772428
Drug: Factor Xa
Normalized name: Anti factor Xa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factor Xa inhibitors/direct thrombin inhibitors
Study: 33774767
Drug: TAS0728 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS0728 at 200 mg BID
Study: 33774767
Drug: TAS0728 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS0728 at 150 mg BID
Study: 33774767
Drug: TAS0728 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAS0728 treatment response
Study: 33775123
Drug: Vascular endothelial
Normalized name: Vascular endothelial growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular endothelial growth factor receptor inhibition
Study: 33775523
Drug: Galsulfase enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galsulfase enzyme replacement therapy (ERT)
Study: 33776633
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment group (6 months treatment)
Study: 33778911
Drug: Independence in
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independence in activities of daily living (ADL)
Study: 33778928
Drug: Etrolizumab autoinjector
Normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab autoinjector (AI) 105 mg
Study: 33780567
Drug: Single-dose, long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose, long-acting intravenous dalbavancin
Study: 37118803
Drug: Furmonertinib 80
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furmonertinib 80 mg orally once daily
Study: 33781934
Drug: Scoring tool
Normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scoring tool for systemic symptoms during aspirin challenge
Study: 33782211
Drug: Gamma Irradiation
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma Irradiation (GI) at a target dose of 50 kGy
Study: 33783067
Drug: BCNU (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCNU (150 mg/m²) and temozolomide
Study: 36039789
Drug: 7-day low-salt
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7-day low-salt diet (3.0 g/day)
Study: 36039789
Drug: 7-day high-salt
Normalized name: Salt solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day high-salt diet (18 g/day)
Study: 33783498
Drug: Rituximab (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (200, 500, 700, and 1000 mg single intravenous dose)
Study: 33785483
Drug: SINE compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: SINE compounds in combination with R-CHOP
Study: 33785483
Drug: SINE compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: SINE compounds
Study: 33785784
Drug: SARS-CoV-2 RNAemia
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 RNAemia (RNAemia) defined as RNA copies above 1000/ml measured by PCR in plasma
Study: 33786329
Drug: Low-Molecular Weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Molecular Weight Hyaluronic Acid (LMW-HA); n = 14; 3 weekly intra-articular injections.
Study: 33786329
Drug: Leukocyte-Poor Platelet-Rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte-Poor Platelet-Rich Plasma (LP-PRP); n = 19; 3 weekly intra-articular injections.
Study: 33786583
Drug: Duvelisib (Duv)
DrugBank: Duvelisib (DB11952)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Duvelisib (Duv) and Venetoclax (Ven) combination
Study: 33787078
Drug: ADI-PEG20 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADI-PEG20 plus low-dose cytarabine (LDC)
Study: 33787078
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine (LDC)
Study: 33787401
Drug: Super-selective intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Super-selective intra-arterial indocyanine green (ICG) administration (5 mL bolus at .125 mg/mL)
Study: 33787401
Drug: Super-selective intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Super-selective intra-arterial indocyanine green (ICG) administration
Study: 33788415
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) atezolizumab coformulated with recombinant human hyaluronidase
Study: 33788415
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) atezolizumab
Study: 33788611
Drug: Integrative Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Medicine Interventions
Study: 33788611
Drug: Pain Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain Medication
Study: 33789635
Drug: Integration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integration of massive and heterogeneous data concerning the patient's environment, personal and familial history, clinical and biological data, imaging, histological results, and microbiota analysis.
Study: 33789635
Drug: Creation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creation of a clinico-biological database prospectively by collecting epidemiological, socio-economic, clinical, biological, pathological, multi-omic data.
Study: 33789723
Drug: Left Ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left Ventricular Assist Device (LVAD) as destination therapy
Study: 33790783
Drug: TangWang Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: TangWang Prescription
Study: 33791217
Drug: HID-PBSCT using
Approvals — FDA: no, EMA: no, PMDA: no
Description: HID-PBSCT using G-PB grafts
Study: 33791217
Drug: HID HSCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HID HSCT using the combination of G-BM and G-PB grafts
Study: 33791349
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no routine oxygen therapy)
Study: 33792221
Drug: CAR-T therapies
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T therapies targeting B-cell maturation antigen (BCMA)
Study: 33792221
Drug: CAR-T therapies
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T therapies targeting other antigens (SLAMF7 and CD44v6)
Study: 33792221
Drug: Current autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current autologous CAR-T therapies
Study: 33792960
Drug: TS-HDS/FGFR3 antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-HDS/FGFR3 antibodies
Study: 39637900
Drug: Alpelisib 300
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib 300 mg/day plus fulvestrant 500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1
Study: 33794207
Drug: Chemoradiotherapy (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (weekly intravenous cisplatin 40 mg/m2) and MRI-based adaptive brachytherapy (IGABT)
Study: 33794832
Drug: SensiumVitals™ patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: SensiumVitals™ patch measuring temperature, heart & respiratory rates applied on arrival for the duration of stay.
Study: 33795193
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hENT1-independent adjuvant chemotherapy)
Study: 33795869
Drug: Intravitreal sepofarsen
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal sepofarsen injection
Study: 33799685
Drug: Posttransplant cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posttransplant cyclophosphamide (PTCy) 50 mg/kg on days +3 and +4 combined with tacrolimus/mycophenolate mofetil (T/MMF) starting day +5
Study: 33799685
Drug: Posttransplant cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posttransplant cyclophosphamide (PTCy) 50 mg/kg combined with T/MMF
Study: 33800872
Drug: Salvage radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage radiation therapy (SRT) at 70 Gy in 35 fractions + locoregional deep hyperthermia (HT) (7-10 sessions)
Study: 33801399
Drug: Trabectedin, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin, administered every three weeks, median of four cycles (range: 1-40), mostly as a second-line treatment (~60% of patients)
Study: 33803049
Drug: solid ASD
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: solid ASD of efavirenz 50 mg
Study: 33803049
Drug: dissolved ASD
Approvals — FDA: no, EMA: no, PMDA: no
Description: dissolved ASD of efavirenz 50 mg
Study: 33803049
Drug: molecular solution
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: molecular solution of efavirenz 3 mg (non-ASD)
Study: 33804976
Drug: Calcium-containing Eggshell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-containing Eggshell Powder (ESP) supplementation, 2.4 g daily for 6 months
Study: 33805731
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy combined with regional hyperthermia (RHT) including radiotherapy with concurrent 5-Fluorouracil (5-FU)/Capecitabine and Oxaliplatin.
Study: 33807097
Drug: Bivalent oral
Normalized name: Non-US bivalent oral polio vaccine (types 1 and 3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent oral vaccine against enteric fever, specific dosage and duration not mentioned.
Study: 33807097
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group not specified, details on control treatment not available.
Study: 33809705
Drug: HIV+ and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV+ and low iron stores (inflammation-unadjusted serum ferritin ≤ 40 µg/L)
Study: 33811052
Drug: Prehabilitation intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prehabilitation intervention including a prehabilitation kit with an advice booklet and respiratory rehabilitation devices, monitored weekly for physical and respiratory rehabilitation, preoperative renutrition, motivational counselling, and iatrogenic prevention.
Study: 33811727
Drug: Gemcitabine 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 800 mg/m²
Study: 33812913
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose escalation with simultaneous integrated boost (SIB) technique, delivering 62.5-64 Gy/25-32 fractions to GTV, with SIB up to 70 Gy for pre-treatment 50% SUVmax area of GTV, plus 2 cycles of chemotherapy (cisplatin and fluorouracil) concurrently and 2 more cycles after radiotherapy.
Study: 33812913
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose escalation with SIB (Level 3&4)
Study: 33812913
Drug: Maximal dose
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal dose of the esophagus (Dmax)
Study: 33813550
Drug: Dexmedetomidine IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine IV administered without a loading dose at age-specific dose regimens 0.2-1.4 µg/kg/hr (< 6 yr) and 0.2-1.0 µg/kg/hr (≥ 6 yr)
Study: 33813550
Drug: Dexmedetomidine IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine IV administered
Study: 33813580
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of subcutaneous injection risk
Study: 33813727
Drug: Prasugrel 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 3.75 mg DAPT
Study: 33813771
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with EDS due to severe sleep-disordered breathing, improving after therapy
Study: 33813842
Drug: Tailored treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored treatment of nonphysiologic hemodynamic adjustments to pregnancy
Study: 33816283
Drug: Cs-131 implant
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cs-131 implant after surgical resection
Study: 33816524
Drug: PT-Cy combined
Normalized name: Cys
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PT-Cy combined with tacrolimus and low-dose ATG
Study: 33817379
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac 25 mg/mL applied after laser microporation of cNF, reapplied twice daily for 3 days.
Study: 33817379
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline applied after laser microporation of cNF, reapplied twice daily for 3 days.
Study: 33818022
Drug: Adjuvant letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant letrozole (2.5 mg/daily) for 5 years
Study: 33818226
Drug: Oral anticoagulants,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants, alone or in combination with antiplatelet (AP)
Study: 33820779
Drug: Sapanisertib plus
Normalized name: sapanisertib
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapanisertib plus exemestane (3 to 5 mg daily in phase IB, 25 mg daily)
Study: 33820779
Drug: Sapanisertib plus
Normalized name: sapanisertib
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapanisertib plus fulvestrant (4 mg daily, 500 mg monthly)
Study: 33820780
Drug: ABBV-085 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-085 monotherapy at 3.6 mg/kg
Study: 33820780
Drug: ABBV-085 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-085 at 3.6 mg/kg every 14 days
Study: 33820783
Drug: Pepinemab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pepinemab (10 mg/kg) with Avelumab (10 mg/kg), every 2 weeks
Study: 33820851
Drug: Secondary antibiotic
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary antibiotic prophylaxis
Study: 33822526
Drug: CAR-T cell
Normalized name: SynKIR-meso CAR-T cells
DrugBank: SynKIR-110 (DB17365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T cell therapy
Study: 33823051
Drug: Migraine-specific medications
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migraine-specific medications
Study: 33823051
Drug: Acute medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute medication use
Study: 33823051
Drug: Migraine-specific medication
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migraine-specific medication use
Study: 33823783
Drug: Sexual risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sexual risk reduction intervention in addition to hepatitis C treatment
Study: 33824433
Drug: Intrabone (IB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrabone (IB) infusion of umbilical cord blood transplantation (UCBT)
Study: 33824442
Drug: 10-day decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day decitabine (20 mg/m2) combined with fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation (allo HCT)
Study: 33824476
Drug: Tepotinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepotinib (500 mg daily)
Study: 33825965
Drug: P2X3-Receptor Antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: P2X3-Receptor Antagonist Gefapixant
Study: 33825965
Drug: Prior medications
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior medications (inhaled/oral steroids, antihistamines, antacids)
Study: 33826106
Drug: Ravulizumab (weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ravulizumab (weight-based doses administered on days 1, 5, 10, and 15)
Study: 33826106
Drug: Ravulizumab (modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ravulizumab (modified dosing regimen)
Study: 33826112
Drug: Eculizumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab treatment (a complement C5 inhibitor)
Study: 33826209
Drug: Omecamtiv mecarbil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omecamtiv mecarbil, dosage and duration not available